New Milestone Reached: 89bio Secures $125 Million Funding for Breakthrough Liver and Cardio-metabolic Therapies

89bio, a San Francisco-based clinical-stage biopharmaceutical company, has successfully raised $125 million in its latest funding round, further propelling its mission to develop innovative therapies for liver and cardio-metabolic diseases. Focused on addressing critical medical needs, 89bio is dedicated to improving the lives of patients suffering from nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) with its lead product candidate, BIO89-100. This specifically engineered glycoPEGylated analog of FGF21 has shown promising Phase 1b/2a results, demonstrating not only a favorable safety and tolerability profile but also significant reductions in liver fat and key lipid markers when administered weekly or bi-weekly. The recent funding will be instrumental in advancing BIO89-100 through its ongoing Phase 2 trial for SHTG and expediting further clinical development efforts aimed at transforming treatment options for patients with liver diseases. 89bio prides itself on a culture rooted in patient-centric values and operates with unwavering integrity and ethical standards. The talented team fosters an environment that encourages collaboration and entrepreneurship, driving scientific rigor in their decision-making. With this substantial financial backing, 89bio is poised to make a significant impact in the biopharmaceutical landscape and enhance the quality of life for individuals battling complex liver and metabolic disorders. The momentum gained from this funding will undoubtedly accelerate the timeline for bringing innovative therapies from the lab to the clinic, underscoring the company's commitment to leading advancements in patient care.